Management of histologically indolent non-Hodgkin's lymphomas.

Histologically indolent lymphomas which represent 40-50% of all non-Hodgkin's lymphomas encompass small lymphocytic lymphomas, follicular lymphomas and other entities more recently described such as mantle cell and marginal zone lymphomas. Their management has benefited from new drugs such as interferon alpha the purine analogues and new treatment modalities especially autologous stem cell transplantation.